Login to Your Account



Clinic Roundup


Friday, March 23, 2012
• Euthymics Bioscience Inc., of Cambridge, Mass., said it started a Phase I trial of EB-1020, a next-generation drug in development for treating adult attention deficit hyperactivity disorder aimed at carrying a low risk of drug abuse liability.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription